Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.789
Sell
RSI(14)
28.728
Sell
STOCH(KDJ)(9,3,3)
13.683
Oversold
ATR(14)
0.741
High Vlolatility
CCI(14)
-82.848
Neutral
Williams %R
90.307
Oversold
TRIX(12,20)
-0.985
Sell
StochRSI(14)
0.000
Sell
Search
Zevra Therapeutics Inc
ZVRAAdd to Watchlist
9.510USD
-0.130-1.35%
Close 07-31 16:00（ET）Quotes delayed by 15 min
562.18MMarket Cap
4.51P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-1.35%
5 Days
-0.16%
1 Month
-31.14%
6 Months
+5.67%
Year to Date
+6.14%
1 Year
-14.40%
Key Figures
9.700Open
9.753High
971.43KVolume
4.51P/E TTM
10.40P/E Dynamic
--Dividend TTM
1.64%Turnover Ratio
9.640Prev. Close
9.340Low
6.80MTurnover
LossP/E Static
2.73P/B
0.00%Div Yield TTM
55.05%ROA
13.16052wk High
0.68Volume Ratio
-105.51MNet Profit
59.11MShares
2.1087EPS TTM
0.91Beta
96.08%ROE
7.16052wk Low
4.29%Amplitude
213.48%Gross Margin
562.18MMarket Cap
-9.59Reward/Risk
3.23%Risk Rate
TradingKey Stock Score of Zevra Therapeutics Inc
Currency: USD Updated: 2026-07-31Key Insights
Zevra Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Zevra Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Zevra Therapeutics Inc Highlights
StrengthsRisks
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 287.71% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 4.51, at a high 3-year percentile range.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 841.10K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.40.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
25.000
Target Price
+155.62%
Upside Space
Zevra Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
9
analysts
Buy
Current Rating
25.000
Target Price
+155.62%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Zevra Therapeutics Inc
ZVRA
9
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
34
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
9.674
Sell
MA10
10.703
Sell
MA20
12.111
Sell
MA50
12.191
Sell
MA100
11.132
Sell
MA200
10.109
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Zevra Therapeutics Inc Info
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
Ticker SymbolZVRA
CompanyZevra Therapeutics Inc
CEOMcfarlane (Neil F)
Websitehttps://zevra.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Zevra Therapeutics Inc (ZVRA)?
The current price of Zevra Therapeutics Inc (ZVRA) is 9.51.
What is the symbol of Zevra Therapeutics Inc?
The ticker symbol of Zevra Therapeutics Inc is ZVRA.
What is the 52-week high of Zevra Therapeutics Inc?
The 52-week high of Zevra Therapeutics Inc is 13.16.
What is the 52-week low of Zevra Therapeutics Inc?
The 52-week low of Zevra Therapeutics Inc is 7.16.
What is the market capitalization of Zevra Therapeutics Inc?
The market capitalization of Zevra Therapeutics Inc is 562.18M.
Is Zevra Therapeutics Inc (ZVRA) currently rated as Buy, Hold, or Sell?
According to analysts, Zevra Therapeutics Inc (ZVRA) has an overall rating of Buy, with a price target of 25.00.
What is the Earnings Per Share (EPS TTM) of Zevra Therapeutics Inc (ZVRA)?
The Earnings Per Share (EPS TTM) of Zevra Therapeutics Inc (ZVRA) is 1.40.